FDA MedWatch - Reminder: Provide Clear Instructions to Patients Who Self-Collect an Anterior Nares (Nasal) Sample: Letter to Health Care Providers

MedWatch - The FDA Safety Information and Adverse Event Reporting Program Reminder: Provide Clear Instructions to Patients Who Self-Collect an Anterior Nares (Nasal) Sample: Letter to Health Care Providers The U.S. Food and Drug Administration (FDA) reminds health care providers to give clear, step-by-step instructions to patients who, in a health care setting, self-collect anterior nasal samples for SARS-CoV-2 testing. Without proper instructions, patients may not collect an adequate sample for testing, which may decrease the sensitivity of the test.  The Letter to Health Care Providers includes:  Details for providing patients with clear instructions for performing anterior nares (nasal) sample self-collection in a health care setting. Recommendations for health care providers. Suggested resources on testing for SARS-CoV-2. Instructions for reporting problems with SARS-CoV-2 testing. Questions? If you have questions about this Letter to Health Care Providers, email COVID19DX@fda.hhs.gov. .

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA